The global Achondroplasia Treatment Market is estimated to be valued at US$ 127.8 million in 2022 and is expected to exhibit a CAGR of 36.5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Achondroplasia is the most common form of disproportionate short stature or dwarfism. It is caused by a mutation or change in the fibroblast growth factor ... Read more

Market Overview:
Achondroplasia is a rare genetic form of dwarfism caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3) gene. Current treatment options are limited to managing physical complications and maximizing quality of life. Emerging gene therapies aim to directly address the underlying FGFR3 gene mutation in order to stimulate bone growth and prevent spinal complications.

Market key trends:
One of the key trends in the Achondroplasia ... Read more